{"id":34397,"date":"2025-05-29T12:51:30","date_gmt":"2025-05-29T04:51:30","guid":{"rendered":"https:\/\/flcube.com\/?p=34397"},"modified":"2025-05-29T12:51:31","modified_gmt":"2025-05-29T04:51:31","slug":"jw-therapeutics-carteyva-receives-fourth-sbla-for-r-r-lbcl","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34397","title":{"rendered":"JW Therapeutics&#8217; Carteyva Receives Fourth sBLA for r\/r LBCL"},"content":{"rendered":"\n<p>JW Therapeutics (<a href=\"https:\/\/www.google.com\/finance\/quote\/2126:HKG\">HKG: 2126<\/a>), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics (a Bristol-Myers Squibb subsidiary) and WuXi AppTec (<a href=\"https:\/\/www.google.com\/finance\/quote\/603259:SHA\">SHA: 603259<\/a>), announced that a supplemental Biological License Application (sBLA) for its cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) has been accepted for review by the National Medical Products Administration (NMPA). This marks the fourth sBLA for Carteyva, targeting second-line relapsed or refractory large B-cell lymphoma (r\/r LBCL), an indication awarded Breakthrough Therapy Designation by the agency in January this year.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>The sBLA is supported by results from a pivotal Phase II study involving patients with r\/r LBCL who were ineligible for autologous stem cell transplant (ASCT) and had failed first-line systemic therapy with CD20-targeted antibodies and anthracyclines. As of January 21, 2025, 49 patients received Carteyva infusion and had at least 3-month follow-up. Among 48 efficacy-evaluable patients, Carteyva demonstrated an objective response rate (ORR) of 81.3% and a complete response rate (CRR) of 54.2%. The incidence of severe (\u2265Grade 3) cytokine release syndrome (CRS) was 4.1%, with no severe neurological toxicity (NT) observed.<\/p>\n\n\n\n<p><strong>Carteyva&#8217;s Approved Indications<\/strong><br>Carteyva, an anti-CD19 autologous CAR-T cell immunotherapy developed by JW Therapeutics, has received three indication approvals in China. These include treatment for relapsed or refractory LBCL after two or more lines of systemic therapy, follicular lymphoma (FL) refractory or relapsing within 24 months of second-line or higher systemic treatment, and recurrent or refractory mantle cell lymphoma (r\/r MCL) that has undergone second-line or higher systemic treatment, including Bruton tyrosine kinase inhibitors (BTKis).<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052800327_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025052800327_c.\"><\/object><a id=\"wp-block-file--media-15b7849a-70b8-4d3b-8baf-1b5813c3809d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052800327_c.pdf\">2025052800327_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052800327_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-15b7849a-70b8-4d3b-8baf-1b5813c3809d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34398,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[428,16,21,77,1165,4021,321,38,1078,362],"class_list":["post-34397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bristol-myers-squibb","tag-cancer","tag-car-t","tag-cell-therapy","tag-hkg-2126","tag-juno-therapeutics","tag-jw-therapeutics","tag-market-approval-filings","tag-sha-603259","tag-wuxi-apptec"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>JW Therapeutics&#039; Carteyva Receives Fourth sBLA for r\/r LBCL - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics (a Bristol-Myers Squibb subsidiary) and WuXi AppTec (SHA: 603259), announced that a supplemental Biological License Application (sBLA) for its cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) has been accepted for review by the National Medical Products Administration (NMPA). This marks the fourth sBLA for Carteyva, targeting second-line relapsed or refractory large B-cell lymphoma (r\/r LBCL), an indication awarded Breakthrough Therapy Designation by the agency in January this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34397\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JW Therapeutics&#039; Carteyva Receives Fourth sBLA for r\/r LBCL\" \/>\n<meta property=\"og:description\" content=\"JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics (a Bristol-Myers Squibb subsidiary) and WuXi AppTec (SHA: 603259), announced that a supplemental Biological License Application (sBLA) for its cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) has been accepted for review by the National Medical Products Administration (NMPA). This marks the fourth sBLA for Carteyva, targeting second-line relapsed or refractory large B-cell lymphoma (r\/r LBCL), an indication awarded Breakthrough Therapy Designation by the agency in January this year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34397\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T04:51:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T04:51:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"JW Therapeutics&#8217; Carteyva Receives Fourth sBLA for r\\\/r LBCL\",\"datePublished\":\"2025-05-29T04:51:30+00:00\",\"dateModified\":\"2025-05-29T04:51:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2903.webp\",\"keywords\":[\"Bristol-Myers Squibb\",\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"HKG: 2126\",\"Juno Therapeutics\",\"JW Therapeutics\",\"Market approval filings\",\"SHA: 603259\",\"WuXi AppTec\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34397#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34397\",\"name\":\"JW Therapeutics' Carteyva Receives Fourth sBLA for r\\\/r LBCL - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2903.webp\",\"datePublished\":\"2025-05-29T04:51:30+00:00\",\"dateModified\":\"2025-05-29T04:51:31+00:00\",\"description\":\"JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics (a Bristol-Myers Squibb subsidiary) and WuXi AppTec (SHA: 603259), announced that a supplemental Biological License Application (sBLA) for its cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) has been accepted for review by the National Medical Products Administration (NMPA). This marks the fourth sBLA for Carteyva, targeting second-line relapsed or refractory large B-cell lymphoma (r\\\/r LBCL), an indication awarded Breakthrough Therapy Designation by the agency in January this year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34397\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2903.webp\",\"width\":1080,\"height\":608,\"caption\":\"JW Therapeutics' Carteyva Receives Fourth sBLA for r\\\/r LBCL\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34397#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JW Therapeutics&#8217; Carteyva Receives Fourth sBLA for r\\\/r LBCL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JW Therapeutics' Carteyva Receives Fourth sBLA for r\/r LBCL - Insight, China&#039;s Pharmaceutical Industry","description":"JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics (a Bristol-Myers Squibb subsidiary) and WuXi AppTec (SHA: 603259), announced that a supplemental Biological License Application (sBLA) for its cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) has been accepted for review by the National Medical Products Administration (NMPA). This marks the fourth sBLA for Carteyva, targeting second-line relapsed or refractory large B-cell lymphoma (r\/r LBCL), an indication awarded Breakthrough Therapy Designation by the agency in January this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34397","og_locale":"en_US","og_type":"article","og_title":"JW Therapeutics' Carteyva Receives Fourth sBLA for r\/r LBCL","og_description":"JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics (a Bristol-Myers Squibb subsidiary) and WuXi AppTec (SHA: 603259), announced that a supplemental Biological License Application (sBLA) for its cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) has been accepted for review by the National Medical Products Administration (NMPA). This marks the fourth sBLA for Carteyva, targeting second-line relapsed or refractory large B-cell lymphoma (r\/r LBCL), an indication awarded Breakthrough Therapy Designation by the agency in January this year.","og_url":"https:\/\/flcube.com\/?p=34397","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-29T04:51:30+00:00","article_modified_time":"2025-05-29T04:51:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34397#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34397"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"JW Therapeutics&#8217; Carteyva Receives Fourth sBLA for r\/r LBCL","datePublished":"2025-05-29T04:51:30+00:00","dateModified":"2025-05-29T04:51:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34397"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34397#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2903.webp","keywords":["Bristol-Myers Squibb","Cancer","CAR-T","Cell-therapy","HKG: 2126","Juno Therapeutics","JW Therapeutics","Market approval filings","SHA: 603259","WuXi AppTec"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34397#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34397","url":"https:\/\/flcube.com\/?p=34397","name":"JW Therapeutics' Carteyva Receives Fourth sBLA for r\/r LBCL - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34397#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34397#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2903.webp","datePublished":"2025-05-29T04:51:30+00:00","dateModified":"2025-05-29T04:51:31+00:00","description":"JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics (a Bristol-Myers Squibb subsidiary) and WuXi AppTec (SHA: 603259), announced that a supplemental Biological License Application (sBLA) for its cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) has been accepted for review by the National Medical Products Administration (NMPA). This marks the fourth sBLA for Carteyva, targeting second-line relapsed or refractory large B-cell lymphoma (r\/r LBCL), an indication awarded Breakthrough Therapy Designation by the agency in January this year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34397#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34397"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34397#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2903.webp","width":1080,"height":608,"caption":"JW Therapeutics' Carteyva Receives Fourth sBLA for r\/r LBCL"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34397#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"JW Therapeutics&#8217; Carteyva Receives Fourth sBLA for r\/r LBCL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34397"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34397\/revisions"}],"predecessor-version":[{"id":34401,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34397\/revisions\/34401"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34398"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}